In the Matter of Certain Modified Vaccinia Ankara (“MVA”) Viruses and Vaccines and Pharmaceutical Compositions Based Thereon; Notice of Commission Decision To Request Supplemental Briefing and To Extend the Target Date for Completion of the Investigation, 3151 [E7-985]

Download as PDF Federal Register / Vol. 72, No. 15 / Wednesday, January 24, 2007 / Notices Estimated Time Per Respondent: 2 hours. Estimated Total Annual Burden Hours: 800. Estimated Total Annualized Cost on the Public: N/A. If additional information is required contact: Tracey Denning, Bureau of Customs and Border Protection, 1300 Pennsylvania Avenue, NW., Room 3.2.C, Washington, DC 20229, at 202– 344–1429. Dated: January 16, 2007. Tracey Denning, Agency Clearance Officer, Information Services Branch. [FR Doc. E7–959 Filed 1–23–07; 8:45 am] BILLING CODE 9111–14–P Dated: January 18, 2007. Richard Bailey, Acting District Manager. [FR Doc. E7–989 Filed 1–23–07; 8:45 am] BILLING CODE 4310–33–P INTERNATIONAL TRADE COMMISSION [Investigation No. 337–TA–550] In the Matter of Certain Modified Vaccinia Ankara (‘‘MVA’’) Viruses and Vaccines and Pharmaceutical Compositions Based Thereon; Notice of Commission Decision To Request Supplemental Briefing and To Extend the Target Date for Completion of the Investigation U.S. International Trade Commission. ACTION: Notice. AGENCY: DEPARTMENT OF THE INTERIOR Bureau of Land Management [OR–130–1020–PH; GP7–0053] Notice of Public Meeting, Eastern Washington Resource Advisory Council Meeting Bureau of Land Management, U.S. Department of the Interior. AGENCY: ACTION: Notice of public meeting. SUMMARY: In accordance with the Federal Land Policy and Management Act of 1976 and the Federal Advisory Committee Act of 1972, the U.S. Department of the Interior, Bureau of Land Management Eastern Washington Resource Advisory Council will meet as indicated below. The Eastern Washington Resource Advisory Council will meet Friday, February 23, 2007 at the Spokane District Office, Bureau of Land Management, 1103 North Fancher Road, Spokane Valley, Washington 99212– 1275. DATES: The meeting will start at 8 a.m., adjourn at 4 p.m., and will be open to the public. The meeting will focus on establishing the Council’s agenda for calendar year 2007. The meeting will also include updates on the status of projects and issues discussed at previous meetings. There will be an opportunity for public comment at 3 p.m. pwalker on PROD1PC71 with NOTICES SUPPLEMENTARY INFORMATION: FOR FURTHER INFORMATION CONTACT: Scott Pavey or Sandie Gourdin, Bureau of Land Management, Spokane District Office, 1103 N. Fancher Road, Spokane Valley, Washington 99212–1275, or call (509) 536–1200. VerDate Aug<31>2005 17:44 Jan 23, 2007 Jkt 211001 SUMMARY: Notice is hereby given that the U.S. International Trade Commission has requested supplemental briefing in the abovecaptioned investigation and has determined to extend the target date for completion of the investigation. FOR FURTHER INFORMATION CONTACT: James A. Worth, Office of the General Counsel, U.S. International Trade Commission, 500 E Street, SW., Washington, DC 20436, telephone (202) 205–3065. Copies of non-confidential documents filed in connection with this investigation are or will be available for inspection during official business hours (8:45 a.m. to 5:15 p.m.) in the Office of the Secretary, U.S. International Trade Commission, 500 E Street, SW., Washington, DC 20436, telephone (202) 205–2000. General information concerning the Commission may also be obtained by accessing its Internet server (http://www.usitc.gov). The public record for this investigation may be viewed on the Commission’s electronic docket (EDIS) at http:// edis.usitc.gov. Hearing-impaired persons are advised that information on this matter can be obtained by contacting the Commission’s TDD terminal on (202) 205–1810. SUPPLEMENTARY INFORMATION: This investigation was instituted on September 23, 2005, based on a complaint filed by Bavarian Nordic A/S of Denmark. The complaint alleged violations of section 337 of the Tariff Act of 1930, as amended, 19 U.S.C. 1337, in the importation into the United States, the sale for importation, and the sale within the United States after importation of certain modified vaccinia ankara (‘‘MVA’’) viruses and vaccines PO 00000 Frm 00045 Fmt 4703 Sfmt 4703 3151 and pharmaceutical compositions based thereon by reason of infringement of various claims of United States Patent Nos. 6,761,893 and 6,913,752. The complaint also alleged violations of section 337 in the importation of certain MVA viruses and vaccines and pharmaceutical compositions based thereon or in the sale of such articles by reason of misappropriation of trade secrets, the threat or effect of which is to destroy or substantially injure an industry in the United States. The complaint named a single respondent, Acambis PLC (‘‘Acambis’’) of the United Kingdom. Only the patent allegations remain in this investigation. After a hearing and post-hearing briefing, the ALJ issued a final initial determination (‘‘final ID’’) on September 6, 2006, finding no violation of section 337. The ALJ held that the patents were infringed but invalid. Bavarian Nordic, Acambis, and the Commission investigative attorney filed petitions for review of the final ID. By notice of November 22, 2006, the Commission determined to review the final ID in its entirety, as well as Order No. 10, to extend the target date for completion of the investigation to January 31, 2007, and to ask the parties for briefing on the issues on review and on remedy, public interest and bonding. The parties submitted their initial and reply briefs on December 12 and December 22, 2006, respectively. In view of information set out in the briefs on review, the Commission has requested briefing on whether this investigation has become or will shortly become moot, and if so, whether the investigation should be terminated. This information includes a press release by Acambis dated November 14, 2006 indicating that its ‘‘proposal is no longer being considered for award as part of the U.S. Government’s Modified Vaccinia Ankara (‘‘MVA’’) smallpox vaccine tender process.’’ To accommodate briefing on this issue, the Commission has determined to extend the target date for completion of this investigation to February 21, 2007. This action is taken under the authority of section 337 of the Tariff Act of 1930, as amended (19 U.S.C. 1337), and in section 210.51(a) of the Commission’s Rules of Practice and Procedure (19 CFR 210.51(a)). Issued: January 19, 2007. By order of the Commission. Marilyn R. Abbott, Secretary to the Commission. [FR Doc. E7–985 Filed 1–23–07; 8:45 am] BILLING CODE 7020–02–P E:\FR\FM\24JAN1.SGM 24JAN1

Agencies

[Federal Register Volume 72, Number 15 (Wednesday, January 24, 2007)]
[Notices]
[Page 3151]
From the Federal Register Online via the Government Printing Office [www.gpo.gov]
[FR Doc No: E7-985]


=======================================================================
-----------------------------------------------------------------------

INTERNATIONAL TRADE COMMISSION

[Investigation No. 337-TA-550]


In the Matter of Certain Modified Vaccinia Ankara (``MVA'') 
Viruses and Vaccines and Pharmaceutical Compositions Based Thereon; 
Notice of Commission Decision To Request Supplemental Briefing and To 
Extend the Target Date for Completion of the Investigation

AGENCY: U.S. International Trade Commission.

ACTION: Notice.

-----------------------------------------------------------------------

SUMMARY: Notice is hereby given that the U.S. International Trade 
Commission has requested supplemental briefing in the above-captioned 
investigation and has determined to extend the target date for 
completion of the investigation.

FOR FURTHER INFORMATION CONTACT: James A. Worth, Office of the General 
Counsel, U.S. International Trade Commission, 500 E Street, SW., 
Washington, DC 20436, telephone (202) 205-3065. Copies of non-
confidential documents filed in connection with this investigation are 
or will be available for inspection during official business hours 
(8:45 a.m. to 5:15 p.m.) in the Office of the Secretary, U.S. 
International Trade Commission, 500 E Street, SW., Washington, DC 
20436, telephone (202) 205-2000. General information concerning the 
Commission may also be obtained by accessing its Internet server 
(http://www.usitc.gov). The public record for this investigation may be 
viewed on the Commission's electronic docket (EDIS) at http://
edis.usitc.gov. Hearing-impaired persons are advised that information 
on this matter can be obtained by contacting the Commission's TDD 
terminal on (202) 205-1810.

SUPPLEMENTARY INFORMATION: This investigation was instituted on 
September 23, 2005, based on a complaint filed by Bavarian Nordic A/S 
of Denmark. The complaint alleged violations of section 337 of the 
Tariff Act of 1930, as amended, 19 U.S.C. 1337, in the importation into 
the United States, the sale for importation, and the sale within the 
United States after importation of certain modified vaccinia ankara 
(``MVA'') viruses and vaccines and pharmaceutical compositions based 
thereon by reason of infringement of various claims of United States 
Patent Nos. 6,761,893 and 6,913,752. The complaint also alleged 
violations of section 337 in the importation of certain MVA viruses and 
vaccines and pharmaceutical compositions based thereon or in the sale 
of such articles by reason of misappropriation of trade secrets, the 
threat or effect of which is to destroy or substantially injure an 
industry in the United States. The complaint named a single respondent, 
Acambis PLC (``Acambis'') of the United Kingdom. Only the patent 
allegations remain in this investigation.
    After a hearing and post-hearing briefing, the ALJ issued a final 
initial determination (``final ID'') on September 6, 2006, finding no 
violation of section 337. The ALJ held that the patents were infringed 
but invalid.
    Bavarian Nordic, Acambis, and the Commission investigative attorney 
filed petitions for review of the final ID. By notice of November 22, 
2006, the Commission determined to review the final ID in its entirety, 
as well as Order No. 10, to extend the target date for completion of 
the investigation to January 31, 2007, and to ask the parties for 
briefing on the issues on review and on remedy, public interest and 
bonding. The parties submitted their initial and reply briefs on 
December 12 and December 22, 2006, respectively.
    In view of information set out in the briefs on review, the 
Commission has requested briefing on whether this investigation has 
become or will shortly become moot, and if so, whether the 
investigation should be terminated. This information includes a press 
release by Acambis dated November 14, 2006 indicating that its 
``proposal is no longer being considered for award as part of the U.S. 
Government's Modified Vaccinia Ankara (``MVA'') smallpox vaccine tender 
process.'' To accommodate briefing on this issue, the Commission has 
determined to extend the target date for completion of this 
investigation to February 21, 2007.
    This action is taken under the authority of section 337 of the 
Tariff Act of 1930, as amended (19 U.S.C. 1337), and in section 
210.51(a) of the Commission's Rules of Practice and Procedure (19 CFR 
210.51(a)).

     Issued: January 19, 2007.
    By order of the Commission.

Marilyn R. Abbott,
Secretary to the Commission.
[FR Doc. E7-985 Filed 1-23-07; 8:45 am]
BILLING CODE 7020-02-P